On Sept. 23, 2020, Sinovac Biotech announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences,…
On Sept. 23, 2020, Johnson & Johnson announced the launch of its large-scale, pivotal, multi-country Phase 3 trial…
On Sept. 22, 2020, Sanofi and GSK announced they had signed agreements with the Government of Canada for…
On Sept. 22, 2020, Sinovac Biotech announced that it had recently commenced phase III clinical trials for its…
On Sept. 22, 2020, Codagenix announced that the Serum Institute of India has begun manufacturing CDX-005, the company’s…
On Sept. 17, 2020, BioNTech announced an agreement with Novartis to acquire their GMP certified manufacturing facility in…
On Sept. 17, 2020, Atossa Therapeutics announced a positive interim safety assessment from the second cohort of healthy…
On Sept. 16, 2020, a study by researchers at La Jolla Institute for Immunology published in the Cell,…
On Sept. 15, 2020, Novavax announced an amendment to its existing agreement with Serum Institute of India which…
On Sept. 15, 2020, Thermo Fisher Scientific announced it was investing more than $140 million to further expand…
On Sept. 15, 2020, Soligenix announced publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and…
On Sept. 15, 2020,Tonix Pharmaceuticals announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001),…
On Sept. 15, 2020, BioNTech announced that had receive a grant of up to 375 million Euro from…
On Sept. 14, 2020, scientists at the Max Planck Institute for Infection Biology in Berlin and the Institut…
On Sept. 14, 2020, Valneva announced a vaccine partnership with the UK government for its inactivated COVID-19 vaccine,…
On Sept. 14, 2020, Dynavax Technologies announced a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant…
On Sept. 12 2020, Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK…
On Sept. 11, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
On Sept. 9, 2020, Merck announced announced that two Phase 3 studies evaluating the safety, tolerability and immunogenicity…
On Sept. 9, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
On Sept. 9, 2020, Sinovac Biotech announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences…
On Sept. 9, 2020, Valneva announced the signing of a new contract, lasting up to three years, with…
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
On Sept. 9, 2020, Pfizer and BioNTech announced that they had submitted an amended protocol to the FDA…
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
On Sept. 9, 2020, iBio announced that it had selected IBIO-201, its LicKMï¾™-ubunit vaccine, as its leading candidate…
On Sept. 8, 2020, the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and…
On Sept. 8, 2020, Vaxart announced pre-publication of a manuscript titled ﾓPreclinical studies of a recombinant adenoviral mucosal…
On Sept. 7, 2020, Pfizer and BioNTech announced that the German regulatory authority, the Paul-Ehrlich-Institut, had approved the…
On Sept. 4, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD),…